Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA granted accelerated approval to sunvozertinib, marketed as Zegfrovy by Dizal, for adults with locally advanced or metastatic non-small cell lung cancer whose tumors carry EGFR exon 20 insertion mutations.
The indication applies after disease progression on or after platinum-based chemotherapy and requires detection by an FDA-approved test. That makes the approval part of the broader precision-oncology shift in which treatment depends on molecular profiling, not only tumor location.
Accelerated approval gives patients earlier access based on response data while requiring confirmatory evidence to verify clinical benefit.
Why It Matters
EGFR exon 20 insertion mutations are a defined lung-cancer subgroup with specialised treatment needs, and new targeted options can change sequencing after chemotherapy.
What to Watch
Watch confirmatory-trial results, companion diagnostic use and how oncologists position sunvozertinib against other EGFR exon 20 therapies.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDALung CancerEGFRPrecision Oncology